Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A3 | P47895 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | SCN10A | Q9Y5Y9 | 9/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.34 |
| ▸ | KIF18A | Q8NI77 | 3/20 | 0.33 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24225601 | 0.83 | SCN10A (0.35) | SCN10ASIGMAR1PIK3CAMTORFLT3 | |
| SCHEMBL24225609 | 0.81 | PDE10A (0.35) | SCN10ASIGMAR1PIK3CAMTORPDE10A | |
| SCHEMBL22322264 | 0.81 | ALDH1A3 (0.40) | ALDH1A3ALDH1A1 | |
| SCHEMBL25215747 | 0.79 | MEN1 (0.39) | ALDH1A1 | |
| SCHEMBL25929683 | 0.78 | SCN10A (0.43) | SCN10ASIGMAR1PIK3CAMTORFLT3 | |
| SCHEMBL22803865 | 0.78 | TRPV1 (0.42) | SCN10ASIGMAR1PIK3CAMTORFLT3 | |
| SCHEMBL30412557 | 0.78 | TRPV1 (0.42) | SCN10ASIGMAR1PIK3CAMTORFLT3 | |
| SCHEMBL29287745 | 0.77 | ALDH1A3 (0.37) | ALDH1A3ALDH1A1PDE10A | |
| SCHEMBL15351824 | 0.77 | SCN10A (0.36) | SCN10ASIGMAR1PIK3CAMTORFLT3 | |
| SCHEMBL15350774 | 0.76 | PTGER4 (0.48) | SCN10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220024906-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2022-01-27 | — | — | US | disclosed |
| US-20220024906-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | NOVARTIS PHARMA AG (CH) | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220024906-A1 | COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH STING ACTIVITY | STING1, CGAS, IRF3 | ALDH1A3 4465/4885ALDH1A1 4654/4885SCN10A 2166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.